Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810880 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HPGDSMEN1LMNAKMT2A | |
| SCHEMBL7669784 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HPGDSMEN1LMNAKMT2A | |
| SCHEMBL14932683 | 0.92 | ALDH1A1 (0.58) | ALDH1A1HPGDSCNR2SMN1; SMN2MMP2 | |
| SCHEMBL30493601 | 0.92 | ALDH1A1 (0.58) | ALDH1A1HPGDSCNR2SMN1; SMN2MMP2 | |
| SCHEMBL20951072 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HPGDSCNR2CA12CA1 | |
| SCHEMBL20951073 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HPGDSCNR2CA12CA1 | |
| SCHEMBL22367131 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HPGDSCNR2CA12CA1 | |
| SCHEMBL24235501 | 0.87 | ALDH1A1 (0.52) | ALDH1A1HPGDSMEN1LMNAKMT2A | |
| SCHEMBL13822102 | 0.86 | ALDH1A1 (0.72) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL15354479 | 0.86 | ALDH1A1 (0.72) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018092725-A1 | p53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | 学校法人東京理科大学 | 2018-05-24 | — | — | WO | disclosed |
| EP-2931724-B1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA LP (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9403824-B2 | Pyridonemorphinan analogs and biological activity on opioid receptors | PURDUE PHARMA L.P. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9340542-B2 | Propellane-based compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150203494-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA L.P. | 2015-07-23 | — | — | US | disclosed |
| US-20150183787-A1 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2015-07-02 | — | — | US | disclosed |
| WO-2015097546-A1 | PROPELLANE-BASED COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR MODULATORS | PURDUE PHARMA L.P. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-8980906-B2 | Pyridonemorphinan analogs and biological activity on opioid receptors | PURDUE PHARMA L.P. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20140187549-A1 | Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2014091295-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA L.P. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-8546533-B2 | Pipecolic linker and its use for chemistry on solid support | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | UNIVERSITE DE MONTPELLIER I (FR) | 2011-06-23 | — | — | US | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183787-A1 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF | OPRL1, OPRK1, OPRD1 | ALDH1A1 214/4885HPGDS 578/4885MEN1 3121/4885 |
| US-20140187549-A1 | Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors | OPRM1, OPRK1, OPRL1 | ALDH1A1 638/4885HPGDS 789/4885MEN1 4421/4885 |
| US-20150203494-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | OPRM1, OPRK1, OPRL1 | ALDH1A1 704/4885HPGDS 842/4885MEN1 4434/4885 |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | ALDH1A1 2560/4885HPGDS 2457/4885MEN1 1693/4885 |
| US-20110152464-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | PRRC2C, VIP, PRRC2A | ALDH1A1 4427/4885HPGDS 1913/4885MEN1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.